Drugs / TNG456
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06810544 | Mar 2025 → Mar 2027 expected | brain neoplasm, glioblastoma, lung adenocarcinoma | Tango Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNG456 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06810544 ↗ |
| Action | Inhibit | “The study drug, TNG456, is a selective PRMT5 inhibitor administered orally.” NCT06810544 ↗ |
| Route | Oral | “administered orally” NCT06810544 ↗ |
| Target | PRMT5 | “The study drug, TNG456, is a selective PRMT5 inhibitor administered orally.” NCT06810544 ↗ |